Corticosteroid injections of hip linked to ‘rapidly destructive hip disease’

Corticosteroid injections are a common treatment option for pain and inflammation in patients with osteoarthritis of the hip. But a new study adds to concerns that hip steroid injections may lead to increased rates of a serious complication called rapidly destructive hip disease (RDHD), according to a paper in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.

Good sleep is just what doctor ordered

In a study released Feb. 22 in JAMA Internal Medicine researchers found that six 20-minute telephone calls over eight weeks coaching participants on how to get better sleep improved their sleep, pain, and daytime function. The improvements in sleep and daytime function persisted 12 months after treatment. One of the lead investigators who has been researching age and sleeping for 40 years offers great tips on getting better sleep. Just because you are aging, does NOT mean your sleep needs to get worse.

Warfarin Use Significantly Increases Risk of Knee and Hip Replacement in People with OA

New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that use of warfarin, a vitamin K drug widely prescribed to prevent blood clots, is associated with a significantly greater risk of knee and hip replacements in patients with osteoarthritis.

Steroid Injections Do Not Hasten the Need for Knee Replacement When Compared to Hyaluronic Acid Treatments for Adults with Knee OA

New research shows that corticosteroid injections for knee OA treatment do not hasten a patient’s progression to a total knee replacement when compared with hyaluronic acid injections. Details of this study was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.

‘Incredibly generous’ $25 million donation to create the Schroeder Arthritis Institute at UHN, consolidating research, education and patient care under one global brand

One in five Canadian adults is currently living with arthritis, a disease causing inflammation of the joints, which can result in chronic, debilitating pain, reduced mobility and premature disability. Arthritis is the leading cause of disability globally. To address this growing crisis, the Schroeder Arthritis Institute, launched with a $25 million donation by philanthropists Walter and Maria Schroeder, will help UHN’s innovative arthritis program become a world-class hub for innovation in research, education and patient care.

CAREER Award Supports Research to Deepen Understanding of Osteoarthritis

Deva Chan, an assistant professor of biomedical engineering at Rensselaer Polytechnic Institute, is leading a team that will study the role that biomechanics plays in the production and function of hyaluronan in an effort to learn more about the factors that affect joint health and osteoarthritis. This research is being supported by a National Science Foundation Faculty Early Career Development (CAREER) Program Award.

Collaboration reveals potential new therapy for osteoarthritis

Osteoarthritis affects 240 million people worldwide and is one of the most common causes of disability in both humans and animals. Currently, no therapeutics exist to prevent this disease, but recent multidisciplinary research at Cornell reveals that the application of a proprietary peptide known as SS-31 may protect cartilage from the injury that leads to arthritis.

Better Biosensor Technology Created for Stem Cells

A Rutgers-led team has created better biosensor technology that may help lead to safe stem cell therapies for treating Alzheimer’s and Parkinson’s diseases and other neurological disorders. The technology, which features a unique graphene and gold-based platform and high-tech imaging, monitors the fate of stem cells by detecting genetic material (RNA) involved in turning such cells into brain cells (neurons), according to a study in the journal Nano Letters.